Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
about
HIV-1 neutralizing antibodies: understanding nature's pathwaysNicotine mediates expression of genes related to antioxidant capacity and oxidative stress response in HIV-1 transgenic rat brain.Human immunodeficiency virus vaccine trialsNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Multi-Parameter Exploration of HIV-1 Virus-Like Particles as Neutralizing Antibody Immunogens in Guinea Pigs, Rabbits and MacaquesStudies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.Modulation of antigen-specific humoral responses in rhesus macaques by using cytokine cDNAs as DNA vaccine adjuvantsCharacterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers.Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development.Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission.Comparing antigenicity and immunogenicity of engineered gp120.Induction of neutralizing antibodies against human immunodeficiency virus type 1 primary isolates by Gag-Env pseudovirion immunization.Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesPurification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.Enhancement of antibodies to the human immunodeficiency virus type 1 envelope by using the molecular adjuvant C3d.Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodiesPerformance of the OraQuick rapid antibody test for diagnosis of human immunodeficiency virus type 1 infection in patients with various levels of exposure to highly active antiretroviral therapy.Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin.Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary virusesEngineering, expression, purification, and characterization of stable clade A/B recombinant soluble heterotrimeric gp140 proteins.Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructsInclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120.Neutralizing antibodies to HIV-1 induced by immunization.Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccinationImportance of the V1/V2 loop region of simian-human immunodeficiency virus envelope glycoprotein gp120 in determining the strain specificity of the neutralizing antibody response.Covalently linked human immunodeficiency virus type 1 gp120/gp41 is stably anchored in rhabdovirus particles and exposes critical neutralizing epitopes.Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization.3-hydroxyphthalic anhydride-modified human serum albumin as a microbicide candidate against HIV type 1 entry by targeting both viral envelope glycoprotein gp120 and cellular receptor CD4.Viral sequence diversity: challenges for AIDS vaccine designs.Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins.
P2860
Q27000480-79B8EED7-42C1-47A1-8FC7-508DF8327F5AQ30278808-DE487E3F-A789-40E8-A192-8DBFA018C7DDQ30424366-A543DBD4-0F5F-40ED-A2B2-57616ED22230Q30431941-2A6D36F6-67E2-4736-B474-9BCC6DA28564Q33683203-F131D245-4D76-462A-9556-B707827F6361Q33785383-FFA86B22-F2C1-4347-A035-3D3B175ABBE6Q33801810-BE2000B6-5100-4A38-A389-E1E87E979780Q33806056-B0B4A094-39A9-4BE2-81CF-B46983D51EC1Q33813526-E0BAD024-5674-4A3A-897F-6E8203A0AC73Q33835295-48651EAC-EA8D-4FDD-AD61-760DD7305DB4Q33836042-663CEC9D-2D18-4C52-A157-2CE96EEFCEC9Q33842152-56109202-8EC7-4107-8054-E7CB3D21B029Q33883887-C9D10493-7272-4200-8E30-461A2CFAD0FFQ33925615-00984E23-76C8-43CB-998C-25C4BE3A9076Q33984309-CB6BF8C0-4702-449F-9304-BC463C3B9DDDQ34142795-8BA5F8CB-25F5-44C5-8519-A4EAD1CB6AD9Q34154514-7EACEA7D-E858-4A61-954B-6BF9BDB757AFQ34332284-C7F4855E-3D99-4BFF-9554-EA5444400FCFQ34466693-F87B6B64-ADC9-40B0-8498-2DCEDE835954Q34982715-AEDFDF09-3543-4959-B738-A4C39AF7550CQ34990508-1E351135-A03B-4F8A-B608-E33E97C14005Q34999293-48531A66-B7F7-401B-9488-651CB970F547Q35077716-CE2C4B38-D767-4DEC-B38C-9A4ECF96AFE7Q35173635-EAC870EA-0F76-4BB0-A8A0-BE252F1264DCQ35569049-5560B2F0-F874-476F-BCBD-5F4CBB8A1D06Q35666057-1D074DE8-CDEF-43BF-ABCA-074D73D73B87Q35677724-EDFDB3E1-DDAF-482D-B43C-896A1BD787C0Q35883032-6323C12C-3109-45EE-89E1-8750EDD51548Q35933555-13C1ED99-BEFD-4E8E-A230-58F86D7A35ABQ36149102-08CE16FF-70D7-4F4E-941B-BC882A78EC7AQ36603515-83E829EA-3E3F-4171-AF4F-A038B1160161Q36804634-8DE861AE-158E-4D61-AE4F-29A8E6DE99E7Q36949880-7E9F7C07-8798-4DF9-B67B-7E27BD327C9EQ37059997-BA7D9B05-6807-4423-A23E-9D915BF54DE5Q37072702-FBC0AE0B-9210-46FD-9A99-49EFD5B37A90Q37258274-7D2E8192-0878-4E4F-9996-ED92A8601712Q37316023-E2C4CB85-15F6-49C9-91DD-BF19EB0BF52FQ37422543-526E861F-5A2A-494E-83EF-B7176939A24DQ37596552-F89339BD-5FFC-4CCE-B6FF-FE09E3DD9EBDQ37730028-E6591AFB-194A-49D6-85FD-80726509F18F
P2860
Antibodies with specificity to native gp120 and neutralization activity against primary human immunodeficiency virus type 1 isolates elicited by immunization with oligomeric gp160.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Antibodies with specificity to ...... ization with oligomeric gp160.
@ast
Antibodies with specificity to ...... ization with oligomeric gp160.
@en
type
label
Antibodies with specificity to ...... ization with oligomeric gp160.
@ast
Antibodies with specificity to ...... ization with oligomeric gp160.
@en
prefLabel
Antibodies with specificity to ...... ization with oligomeric gp160.
@ast
Antibodies with specificity to ...... ization with oligomeric gp160.
@en
P2093
P2860
P1433
P1476
Antibodies with specificity to ...... nization with oligomeric gp160
@en
P2093
Burnett PR
Hallberg PL
Kalyanaraman V
Kaminski RW
Mascola JR
Rechtman DJ
VanCott TC
P2860
P304
P407
P577
1997-06-01T00:00:00Z